How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential

Drug Metabolism and Disposition

Volumn 39, Issue 10, 2011, Pages 1779-1783

  Kraynov, Eugenia ^a   Martin, Steven W ^b   Hurst, Susan ^a   Fahmi, Odette A ^a   Dowty, Martin ^a   Cronenberger, Carol ^a   Loi, Cho Ming ^a   Kuang, Bing ^a   Fields, Owen ^a   Fountain, Scott ^a   Awwad, Michel ^a   Wang, Diane ^a  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOKINE; DRUG METABOLIZING ENZYME; DRUG RECEPTOR; FC RECEPTOR; PROTEIN DERIVATIVE;

COMBINATION CHEMOTHERAPY; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG EFFECT; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOXICITY; DRUG TRANSPORT; HUMAN; PHARMACODYNAMICS; POLYPHARMACY; POPULATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SHORT SURVEY;

BIOLOGICAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEINS;

EID: 80053162520     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.040808     Document Type: Short Survey

References (12)

1. Amgen, Inc. (2007) Amgen Clinical Study Report: 20050137. An open-label, randomized, 2-part, parallel design study to characterize the effect of heparin on palifermin pharmacokinetics and the effect of palifermin on heparin pharmacodynamics in healthy subjects. Amgen, Inc., Thousand Oaks, CA.
2. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832. (Pubitemid 36759050)
3. Bunescu A, Seideman P, Lenkei R, Levin K, and Egberg N (2004) Enhanced Fcγ receptor I, αMβ2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J Rheumatol 31:2347-2355. (Pubitemid 39603080)
4. Duan JZ (2007) Applications of population pharmacokinetics in current drug labelling. J Clin Pharm Ther 32:57-79.
5. Huang SM, Zhao H, Lee JI, Reynolds K, Zhang L, Temple R, and Lesko LJ (2010) Therapeutic protein-drug interactions and implications for drug development. Clin Pharmacol Ther 87: 497-503.
6. Lee JI, Zhang L, Men AY, Kenna LA, and Huang SM (2010) CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet 49:295-310.
7. Morgan ET (2009) Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 85:434-438.
8. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, et al. (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205-216. (Pubitemid 351185732)
9. Prandota J (2005) Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. Am J Ther 12:254-261.
10. Strehlau J, Pape L, Offner G, Nashan B, and Ehrich JH (2000) Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet 356:1327-1328.
11. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, et al. (2003) Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25:1700-1721. (Pubitemid 36801943)
12. Zhou H and Davis HM (2009) Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov Today 14:891-898.